TY - JOUR
T1 - Personalizing Prophylactic Radiotherapy for Hip Heterotopic Ossification: An AMSTAR-2 Compliant Review of Meta-analyses
AU - Galietta, Erika
AU - Gaiani, Luca
AU - Giannini, Claudio
AU - Sambri, Andrea
AU - Buwenge, Milly
AU - Macchia, Gabriella
AU - Deodato, Francesco
AU - Cilla, Savino
AU - Strigari, Lidia
AU - Arcelli, Alessandra
AU - Fiore, Michele
AU - Cammelli, Silvia
AU - DE Paolis, Massimiliano
AU - Morganti, Alessio Giuseppe
PY - 2024
Y1 - 2024
N2 - Background/Aim: Heterotopic ossification (HO) is a common complication following total hip arthroplasty. Various prophylactic treatments have been proposed, including radiotherapy (RT). This review summarizes the evidence from meta-analyses on the efficacy of RT in preventing hip HO. Materials and Methods: A literature search was conducted on PubMed. The quality of the meta-analyses was assessed using the AMSTAR-2 tool. Results: Seven meta-analyses were included. One meta-analysis reported a significant reduction in HO occurrence after RT compared to the control group. Comparing RT and nonsteroidal anti-inflammatory drugs, one and two meta-analyses showed significantly greater efficacy of RT in preventing severe HO and better outcomes in patients receiving drugs, respectively. Regarding RT settings, the postoperative and preoperative RT were each supported by one meta-analysis. Furthermore, two meta-analyses showed an advantage of multi-fractionated RT over single fraction RT. The overall confidence rate of the meta-analyses was moderate, low, and critically low in one, three, and three meta-analyses, respectively. Conclusion: RT is a confirmed prophylactic intervention for HO. However, the precise optimization of timing, dosage, and fractionation requires elucidation. Future research should focus on the development of predictive models through large-scale data collection and advanced analytics to refine individualized treatment strategies and assess RT comparative effectiveness with drugs.
AB - Background/Aim: Heterotopic ossification (HO) is a common complication following total hip arthroplasty. Various prophylactic treatments have been proposed, including radiotherapy (RT). This review summarizes the evidence from meta-analyses on the efficacy of RT in preventing hip HO. Materials and Methods: A literature search was conducted on PubMed. The quality of the meta-analyses was assessed using the AMSTAR-2 tool. Results: Seven meta-analyses were included. One meta-analysis reported a significant reduction in HO occurrence after RT compared to the control group. Comparing RT and nonsteroidal anti-inflammatory drugs, one and two meta-analyses showed significantly greater efficacy of RT in preventing severe HO and better outcomes in patients receiving drugs, respectively. Regarding RT settings, the postoperative and preoperative RT were each supported by one meta-analysis. Furthermore, two meta-analyses showed an advantage of multi-fractionated RT over single fraction RT. The overall confidence rate of the meta-analyses was moderate, low, and critically low in one, three, and three meta-analyses, respectively. Conclusion: RT is a confirmed prophylactic intervention for HO. However, the precise optimization of timing, dosage, and fractionation requires elucidation. Future research should focus on the development of predictive models through large-scale data collection and advanced analytics to refine individualized treatment strategies and assess RT comparative effectiveness with drugs.
KW - Heterotopic ossification
KW - hip
KW - intensity-modulated radiation therapy
KW - prophylaxis
KW - radiotherapy
KW - review
KW - Heterotopic ossification
KW - hip
KW - intensity-modulated radiation therapy
KW - prophylaxis
KW - radiotherapy
KW - review
UR - https://publicatt.unicatt.it/handle/10807/326081
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85197171361&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85197171361&origin=inward
U2 - 10.21873/invivo.13603
DO - 10.21873/invivo.13603
M3 - Article
SN - 0258-851X
VL - 38
SP - 1530
EP - 1536
JO - In Vivo
JF - In Vivo
IS - 4
ER -